{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03321045",
            "orgStudyIdInfo": {
                "id": "IRB-170220004"
            },
            "organization": {
                "fullName": "University of Alabama at Birmingham",
                "class": "OTHER"
            },
            "briefTitle": "Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness",
            "officialTitle": "PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "positron-emission-tomography-pet-imaging-with-zirconium-trastuzumab-for-prediction-of-targeted-therapy-effectiveness"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-01",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2017-11-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2017-10-19",
            "studyFirstSubmitQcDate": "2017-10-24",
            "studyFirstPostDateStruct": {
                "date": "2017-10-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-01-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-01-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Suzanne E. Lapi, PhD",
                "investigatorTitle": "Associate Professor of Radiology and Director, Cyclotron Facility",
                "investigatorAffiliation": "University of Alabama at Birmingham"
            },
            "leadSponsor": {
                "name": "University of Alabama at Birmingham",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are proposing to perform a pilot study with goals of demonstrating the feasibility of imaging breast cancer patients with 89Zr-trastuzumab-PET/MRI, evaluating the relationship between tumor 89Zr-trastuzumab uptake and in vitro positivity of HER2, assessing the relationship between 89Zr-trastuzumab uptake and response to HER2 therapy."
        },
        "conditionsModule": {
            "conditions": [
                "Breast Cancer"
            ],
            "keywords": [
                "89Zr-Trastuzumab, HER2 Imaging"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "DIAGNOSTIC",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "[89Zr]-Df-Trastuzumab",
                    "type": "EXPERIMENTAL",
                    "description": "\\[89Zr\\]-Df-Trastuzumab \\[89Zr\\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 millicurie (mCi) at the time of injection. The amount of injected drug is 5 mg of Trastuzumab. 5-6 days post injection the patients will undergo PET/MRI imaging.",
                    "interventionNames": [
                        "Drug: [89Zr]-Df-Trastuzumab",
                        "Diagnostic Test: PET/MRI Imaging"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "[89Zr]-Df-Trastuzumab",
                    "description": "\\[89Zr\\]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.",
                    "armGroupLabels": [
                        "[89Zr]-Df-Trastuzumab"
                    ]
                },
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "PET/MRI Imaging",
                    "description": "5-6 days post injection the patients will undergo PET/MRI imaging.",
                    "armGroupLabels": [
                        "[89Zr]-Df-Trastuzumab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Investigate the use of [89Zr]-Df-Trastuzumab as a HER2 imaging agent",
                    "description": "To measure the diagnostic quality (with standardized uptake values) of PET/MRI imaging with \\[89Zr\\]-Df-Trastuzumab in patients with newly diagnosed breast cancer.",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Be at least 18 years of age.\n* Diagnosis of HER2 positive breast cancer as defined by to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2018 guidelines: Immunohistochemistry (IHC) 3+ OR Single prove In situ hybridization (ISH) with average HER2 copy number \\>= 6 OR dual probe ISH with both average HER2 copy number \\>= 4 AND HER2 to CEP17 ratio \\>=2\n* Patients eligible for radiation therapy or systemic therapy using a regimen containing at least one anti-HER2 agent\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 and 1\n* Ejection fraction greater than 50% by echocardiogram or multiple-gated acquisition (MUGA) scans\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Pregnancy\n* Inability to lie still for the imaging study\n* Weight over 350 lbs., due to the scanner bore size\n* Contraindication for MRI study (e.g. non-removable metal implants or certain tattoos)",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Denise Jeffers, PharmD",
                    "role": "CONTACT",
                    "phone": "205-975-6469",
                    "email": "charlottejeffers@uabmc.edu"
                },
                {
                    "name": "Sebastian Eady, BS",
                    "role": "CONTACT",
                    "phone": "2059962636",
                    "email": "smeady@uabmc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Suzanne E Lapi, PhD",
                    "affiliation": "University of Alabama at Birmingham",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "The Kirklin Clinic",
                    "status": "RECRUITING",
                    "city": "Birmingham",
                    "state": "Alabama",
                    "zip": "35249",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.52066,
                        "lon": -86.80249
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068878",
                    "term": "Trastuzumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M325",
                    "name": "Trastuzumab",
                    "asFound": "Follow-up",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}